New Haven drug developer Rib-X Pharmaceutical Inc. named former Boston biotech executive Mark Leuchtenberger as president and chief executive officer and a director, effective immediately.
Susan Froshauer, who previously was CEO, moves to a new role as chief scientific officer, Rib-X said Tuesday.
Founded in 2001, Rib-X has raised more than $148 million in equity and debt financing to refine antibiotic treatments for skin and tissue ailments caused by drug-resistant bacteria.
Leuchtenberger previously was president and CEO of Targanta Therapeutics Corp. in Boston, which went public in 2007 with a valuation of $210 million to market an antibiotic, according to Xconomy Boston.
Two years later, Targanta was sold to The Medicines Co. in New Jersey for $42 million after the Food & Drug Administration rejected its application to market the drug, Xconomy Boston said on its Web site.
He also is a former Biogen executive who is chairman of MassBio, that state’s biotechnology promoter, and a director of Bosto’s Beth Israel Deaconess Medical Center.
Leuchtenberger has an MBA from Yale and an undergraduate degree from Wake Forest University.
